Background This study aimed to investigate whether oestradiol differs between premenopausal women with and without type 1 diabetes and whether levels are associated with such factors as age, reproductive history or diabetes management.
Introduction
Women with type 1 diabetes experience shorter fertility with delayed menarche [1] and earlier menopause [2] and higher rates of menstrual irregularities and amenorrhoea [3] compared with women without diabetes. Poor glycaemic control [3] may be associated with menstrual irregularities in type 1 diabetes; however, the physiological mechanisms leading to these reproductive changes are poorly understood. Several processes may be involved: premature ovarian ageing [4], higher ovarian autoantibody levels [5] , disruption of the hypothalamicpituitary-ovarian (HPO) axis [6] and higher frequency of ovarian hyperandrogenism and polycystic ovarian syndrome [7, 8] as compared with those in controls.
Alterations in menstruation and ovarian function affect circulating sex hormones, and differences have been described between women with type 1 diabetes and controls [9, 10] . Most studies found similar total oestradiol in female adolescents [7, [11] [12] [13] [14] and premenopausal women [8, [13] [14] [15] with and without type 1 diabetes; however, others found premenopausal women with type 1 diabetes have lower [16] [17] [18] or higher [19] total oestradiol than controls. These conflicting findings may result from differences in timing during the menstrual cycle [7, 13, 17] , use of smaller sample sizes (<100) [8, 12, 14, 18] or residual confounding due to limited matching of cases and controls and/or limited statistical adjustment (i.e. the majority of studies did not report controlling for confounders) [7, 8, 11, 12, [14] [15] [16] [17] [18] [19] .
Data are lacking regarding the association of oestradiol with either type 1 diabetes duration or management (e.g. glycaemic control and insulin regimen), with just one study reporting no correlation between total oestradiol and postprandial blood glucose [16] . However, taking the previous literature as a whole, some variation in oestradiol between women with and without type 1 diabetes may be related to evolving diabetes management (e.g. intensive insulin therapy and changes in HbA 1c goals) [7] over time. Many of these studies are decades old [15] [16] [17] 19, 20] , with more contemporary studies demonstrating (non-significant) trends towards higher oestradiol in women with type 1 diabetes compared with controls [4, 13, 14, 21] , potentially related to insulin's anabolic effect on ovarian steroidogenesis [22] . Along with only limited investigation of the association of diabetes management with oestradiol, these previous studies also did not explore how oestradiol may be differentially associated with reproductive history, with just one older study reporting lower oestradiol in women with type 1 diabetes with amenorrhoea compared with those with normal menstrual cycles [15] .
As our previous study found that type 1 diabetes negatively affects bone mineral density in premenopausal women and oestradiol is a major determinant of bone mineral density, we wanted to determine whether oestradiol levels differ by the presence of type 1 diabetes. To evaluate this, we compared total and bioavailable oestradiol along with sex hormone-binding globulin (SHBG) between premenopausal women with type 1 diabetes (~80% on intensive insulin therapy) and matched controls without diabetes, adjusting for relevant confounders (e.g. reproductive history). While some older studies found lower levels of oestradiol in women with type 1 diabetes compared with controls [16, 17] , based on the more contemporary literature, we hypothesized that women with type 1 diabetes, particularly those on intensive insulin therapy, may now have higher oestradiol than matched controls without diabetes. We also investigated whether reproductive history and general health management (and diabetes management for those with type 1 diabetes) were associated with sex hormones in these young women, examining effect modification by the presence of diabetes, to elucidate potential mechanisms differentially affecting sex hormones in women with and without type 1 diabetes.
Materials and methods

Study design and sample
The Wisconsin Diabetes Registry Study (WDRS) is a population-based cohort of 597 (288 female) incident cases of type 1 diabetes, diagnosed ≤30 years of age, from 28 contiguous counties in Wisconsin, enrolled between May 1987 and April 1992 [23] . Type 1 diabetes was defined by the presence of polyuria and polydipsia with initiation of exogenous insulin therapy. The WDRS examined longitudinal changes in glycaemic control and microvascular and macrovascular complications in type 1 diabetes. In January 2005, 191 participants met enrolment criteria for a smaller ancillary study (Figure 1 ) specifically on bone health in premenopausal women with type 1 diabetes [24] : female, 18-50 years of age, living in Wisconsin and with continued participation in WDRS. Thirteen were lost to follow-up. Of those contacted, 17 women were ineligible because of entering menopause, pregnancy or breastfeeding within the last 3 months. Of the remainder, 89 eligible women, representative of the women from the population-based WDRS [24] , participated in the ancillary study between February and December 2005. The participants identified a female control without diabetes (in priority order) as a full or half sister, female cousin, niece/aunt or female friend of similar race/ethnicity and age (within 5 years, up to 10 if needed); 76 eligible controls participated. The Institutional Review Board at the University of WisconsinMadison approved the study, and participants provided written informed consent at enrollment and all study visits.
Data collection and variables
Blood samples During the ancillary study visit, venipuncture was performed to collect blood from all participants to measure sex hormones and recent glycaemic control (HbA 1c ). Samples were collected by one phlebotomist, without regard to fasting, time of day or year. However, because sex hormones vary during the menstrual cycle, study visits were scheduled during days 20-24 of the participants' cycles, where oestrogen would plateau (approximating a steady state). Additionally, study personnel contacted the women after the study visit to determine the first day of their next menstrual cycle, to allow more precise adjustment for timing in the menstrual cycle during statistical analysis if needed. An aliquot of whole blood was taken for HbA 1c testing. The blood samples were then immediately centrifuged, and a serum pregnancy test conducted, with all results being negative. Serum was then aliquoted for the sex hormone assays and frozen to À80°C until testing.
Sex hormones (dependent variables)
Serum bioavailable (free and albumin-bound fractions) and total (bioavailable and SHBG-bound fractions) 17β-oestradiol were determined by the InterScience Institute (Inglewood, CA, United States). As the ancillary study solely focused on bone outcomes and oestradiol is the pivotal hormone in maintaining bone density [25] , other steroid hormones [e.g. follicle-stimulating hormone (FSH), luteinizing hormone (LH) and testosterone] were not measured. Total oestradiol was determined by radioimmunoassay utilizing a specific conjugated antibody against oestradiol. Radio partition chromatography was used to determine bioavailable oestradiol. Samples were evenly distributed by diabetes status within and between assay runs, conducted in two batches during data collection. The intra-assay coefficient of variation (CV) for both was 13%. The inter-assay CV was ≤17% for total and ≤25% for bioavailable oestradiol. Serum SHBG was measured by chemiluminescent immunoassay, performed monthly by Fairview Diagnostic Labs (Minneapolis, MN, United States). The intra-assay and inter-assay CVs were 20% and ≤15%, respectively.
Independent variables
General health management (all women). Height was measured using a standard stadiometer height rod, weight was measured with a calibrated healthometer (Bridgeview, IL, United States) physician beam scale and body mass index (BMI) was calculated. Waist-to-hip ratio was calculated by averaging two measurements of the waist and hip circumferences. The study examiner collected information on physical activity (quantified as energy expenditure per day and hours per week) using the Five-City Project physical activity assessment [26] .
Diabetes management (women with type 1 diabetes). Age at diagnosis and duration of type 1 diabetes (years between diagnosis and ancillary study visit) were obtained from the WDRS. A self-administered questionnaire as part of the ancillary study collected frequency of blood glucose self-monitoring, insulin dose (analysed as units per Reproductive history (all women). Reproductive history (e.g. age at menarche, history of pregnancies/breastfeeding and average menstrual cycle length) was collected during the ancillary study using a detailed self-administered questionnaire. The study examiner collected data on hormonal contraceptive use (using photographs of all forms to ensure accurate recall), with the women indicating duration and intervals of use. Before statistical analysis, variables encompassing multiple reproductive history parameters were created: (1) number of reproductive years = duration between menarche and the ancillary study visit; (2) number of reproductive years with suppressed ovarian function (SuppOvFx) = total time after menarche using hormonal contraceptives plus time spent pregnant or breastfeeding; and (3) number of reproductive years with unsuppressed ovarian function (UnsuppOvFx) = difference between (1) and (2), years since menarche minus duration on hormonal contraceptives/pregnant/breastfeeding.
Statistical analysis
Statistical analysis was performed using SAS, version 9.3 (SAS Institute, Cary, NC, United States). Significance was defined as p < 0.05. Skewed variables were log transformed (e.g. SHBG) or categorized if skewness remained after transformation (e.g. menstrual cycle length). One bioavailable oestradiol value in a woman with diabetes was excluded because it was an influential outlier. Differences in sample characteristics by diabetes status were determined, accounting for the matching (non-independence) between women with and without type 1 diabetes, using linear (PROC MIXED to compare means) and nonlinear (PROC GLIMMIX to compare proportions) mixed regression models with a random intercept, specifying the matched pair number in the subject option. Unadjusted and multivariable linear mixed regression analysis (also accounting for matching) was then conducted to examine differences in sex hormone levels between women with and without type 1 diabetes. During multivariable regression analysis, potential confounding by each independent variable was assessed; only variables producing a ≥10% change (in either direction) in the diabetes status regression coefficient were retained in the final model. Participants were then stratified by diabetes status, and correlations between sex hormones and independent variables were determined using Pearson correlation. Multivariable linear regression models estimating each sex hormone separately for women with and without type 1 diabetes were then built by entering all independent variables with p < 0.15 from their respective Pearson correlations and then removing non-significant (p ≥ 0.05) variables using a backwards stepwise approach to obtain the final models. Interactions between covariates in the final models were tested and retained if significant. Any covariate significant for women with type 1 diabetes but not controls (except diabetes parameters), and vice versa, was tested for effect modification by diabetes status on its association with the sex hormone using multivariable linear mixed regression analysis using the entire sample, accounting for matching, and presented when significant. The only significant interactions found were with UnsuppOvFx and use of hormonal contraceptives on total oestradiol levels in women with type 1 diabetes and, in all the women, UnsuppOvFx and diabetes status on total oestradiol levels. To plot the interactions, the respective models' regression coefficients were used to calculate total oestradiol levels in 5-year intervals of UnsuppOvFx (from 0 to 35 years) for users/non-users of hormonal contraceptives and cases/controls, respectively.
Results
The mean (standard deviation) ages of women with type 1 diabetes and controls were 27.9 (6.8) and 28.4 (8.2) years, respectively. The sample was 98% non-Hispanic White. The two matched groups were similar (Table 1) , except more women with diabetes had ongoing amenorrhoea (p = 0.03) or longer intervals between menstrual cycles (p = 0.008). Among women with type 1 diabetes, mean age at diagnosis was 11.9 (6.7) years, and mean disease duration was 16.0 (1.5) years. The average HbA 1c for women with diabetes was 8.1% (65 mmol mol À1 ), while all controls had normal values ≤6.0% (≤42 mmol mol
À1
). There were no differences in mean total or bioavailable oestradiol between women with and without type 1 diabetes in either the unadjusted or adjusted model (p ≥ 0.74; Table 2 ). After adjustment for current oestrogen + progesterone contraceptive use and average menstrual cycle length, mean SHBG was significantly higher in women with diabetes than in controls (p = 0.02). Of note, these covariates did not function as intermediates but as negative confounders, as adjusting for them increased the effect size. No additional adjustments altered these results. 
Reproductive history independent variables
Total and bioavailable oestradiol were lower, and SHBG was higher in women currently using oestrogen + progesterone contraceptives versus nonusers, in both groups of women. Furthermore, only in women with diabetes did current use of oestrogen + progesterone contraceptives modify the association between total oestradiol and number of reproductive years with UnsuppOvFx, such that the association between total oestradiol and years with UnsuppOvFx was positive in non-users, while null to negative in current users (Figure 2A ; interaction p = 0.03). When number of reproductive years with SuppOvFx replaced UnsuppOvFx in the model, the interaction was not significant (p = 0.63), nor could total number of reproductive years or current age replace UnsuppOvFx (interactions p ≥ 0.05). Additionally, adjusting the model for current insulin dose, use of intensive insulin therapy/pump, HbA 1c , current age, age at diabetes diagnosis relative to age at menarche (i.e. exogenous insulin use prior to menarche), mean menstrual cycle length, amenorrhoea or precise timing of the blood draw in the menstrual cycle did not change the significant associations/interaction with UnsuppOvFx.
Analysing all women together, diabetes status was also found to be an effect modifier of the association of total oestradiol with UnsuppOvFx, with a positive association only in women with type 1 diabetes, not in controls ( Figure 2B ; interaction p = 0.0005). Stratifying the total sample into two groups above and below the median UnsuppOvFx duration (9 years), we find that women with type 1 diabetes had significantly lower total oestradiol (β = À43. 2 oestradiol and duration of UnsuppOvFx were found only in women with diabetes and not controls (interaction p = 0.01), but not for SHBG (interaction p = 0.98).
Health/diabetes management independent variables
In women with type 1 diabetes, lower bioavailable oestradiol and higher SHBG were associated with higher eGDR (reflecting greater insulin sensitivity). Higher SHBG was also associated with lower exogenous insulin dose, lower BMI, greater weekly physical activity and older (premenopausal) age. Total and bioavailable oestradiol were not associated with current insulin dose, intensive insulin therapy, pump use or HbA 1c . In the control group, higher SHBG was also related to lower BMI. Total and bioavailable oestradiol were not associated with age in either group.
Discussion
While previous studies have analysed oestradiol levels in female adolescents and premenopausal women with type 1 diabetes, to our knowledge, this is the first study to find that in premenopausal women with type 1 diabetes, total and bioavailable oestradiol may be positively associated with the duration of their reproductive years where ovarian function was unsuppressed (UnsuppOvFx) by hormonal contraceptives, pregnancy and/or breastfeeding. In contrast, there was no association with UnsuppOvFx in controls. Furthermore, we found that women with type 1 diabetes appear to have lower total oestradiol with a shorter duration and higher oestradiol with a longer duration of UnsuppOvFx. This effect modification by diabetes of the association of total ( Figure 2B ) and bioavailable oestradiol with UnsuppOvFx resulted in no difference in the overall mean levels between women with and without type 1 diabetes (Table 2 ). This dichotomy of either lower or higher oestradiol in women with type 1 diabetes depending on their duration of UnsuppOvFx may also explain in part the inconsistent results in prior studies. Importantly, the positive association with oestradiol appears to be specific for UnsuppOvFx, as neither current age nor total reproductive years could replace UnsuppOvFx in the statistical models. While oestradiol levels do change with age, the wide age range in this study allowed the examination of the effect of age, finding that the duration of UnsuppOvFx is more strongly associated with oestradiol levels than either age or total reproductive years.
Some previous studies found lower oestradiol in premenopausal women with type 1 diabetes compared with controls [16] [17] [18] . In addition, female adolescents with type 1 diabetes did not exhibit the increase in oestradiol across puberty that female adolescents without diabetes did [7] . Earlier studies hypothesized that lower oestradiol might be due to disruption of the HPO axis, in particular, an attenuated hypothalamic release of gonadotropinreleasing hormone, with a diminished pituitary LH response [6] . Our finding that the lowest levels of oestradiol appear to be specific to women with type 1 diabetes with a shorter duration of UnsuppOvFx is consistent with these previous results demonstrating lower oestradiol across puberty (i.e. with a shorter duration of UnsuppOvFx) in female adolescents with type 1 diabetes compared with controls [7] . In contrast, one study reported significantly higher follicular phase oestradiol in women with type 1 diabetes compared with controls [19] , while several others found similar trends that did not reach statistical significance [4, 13, 14, 21] . Further, studies of postmenopausal women with insulin-dependent diabetes (likely both type 1 and type 2 diabetes) also found higher oestrogen compared with that in controls [29] . Again, our results indicating an association of oestradiol with duration of UnsuppOvFx in women with type 1 diabetes offer a possible explanation for these differing results in prior studies.
The higher oestradiol found in women with type 1 diabetes with longer UnsuppOvFx may be related to an additive effect of cumulative years of apparent ovulation with long-term exogenous insulin therapy potentially leading to greater oestradiol production. Given this possibility, it is important to note that a recent study found no difference in the rate of ovulation between women with and without type 1 diabetes [21] . Normally, insulin is secreted into the portal circulation, where the liver eliminates a significant portion before it reaches the systemic circulation [30] . When insulin is administered subcutaneously, as in type 1 diabetes, it enters the systemic circulation without undergoing this first-pass metabolism, resulting in hepatic hypoinsulinaemia and systemic hyperinsulinaemia [31] . Insulin has multiple effects on ovarian function including reduction of ovarian follicular apoptosis [32] and stimulation of steroidogenesis in human ovarian cells in vitro [22] . Indeed, adult women with type 1 diabetes have both greater ovarian volume and number of follicles, hypothesized due to the effects of exogenous insulin therapy [8] .
A recent review stated that over the last decade, reproductive manifestations of type 1 diabetes in girls have changed from symptoms caused by insulin deficiency to those caused by insulin excess [33] . This corresponds with changing diabetes management, with intensive insulin therapy and insulin pump use becoming standard. As few previous studies reported insulin regimens, it is not possible to determine the relationship between oestradiol and insulin in prior research. Because almost 80% of our sample was on intensive insulin therapy, there was likely some resulting hyperinsulinaemia. However, as current insulin dose and treatment intensity were not associated with oestradiol as originally hypothesized, perhaps the long-term exposure to higher levels of insulin contributes to the gradually increasing oestradiol production with UnsuppOvFx.
With regard to SHBG, levels were significantly higher in women with type 1 diabetes than in controls, after adjusting for hormonal contraceptive use and mean menstrual cycle length, with no variation by duration of UnsuppOvFx. Compared with controls, female adolescents and premenopausal women with type 1 diabetes were found to have similar [8, 9, 15, 18 ] to higher [7, 8, 14] SHBG and postmenopausal women with insulin-dependent diabetes to have higher SHBG [29] in prior research. Perhaps the prior findings of no difference in SHBG between women with and without type 1 diabetes might be due to lack of adjustment for important confounders such as hormonal contraceptive use and menstrual cycle length, both having demonstrated associations with SHBG [15, 34] . The higher SHBG in women with type 1 diabetes is likely a function of the known negative association between SHBG and insulin [35] , specifically, the hepatic upregulation of SHBG production in response to hepatic hypoinsulinaemia despite the systemic hyperinsulinaemia that results from exogenous insulin use [36] .
In women with type 1 diabetes, higher SHBG was associated with lower insulin dose and higher eGDR, both reflecting lower insulin resistance, while higher bioavailable oestradiol was associated with lower eGDR, again consistent with SHBG's negative associations with insulin [35] and insulin resistance [37] . In women with type 1 diabetes, higher SHBG was also associated with older premenopausal age [35] and greater weekly physical activity, both similar to women without diabetes [35, 38] . Lastly, in both groups, higher SHBG was related to lower BMI, potentially a function of the strong negative association between SHBG and leptin [39] .
The current study also demonstrated that, in women both with and without type 1 diabetes, current hormonal contraceptive use was associated with lower total and bioavailable oestradiol and higher SHBG. Lower oestradiol results from hormonal contraceptives' suppression of the HPO axis, prevention of ovulation and inhibition of the rise in oestrogen [40] . Higher SHBG is related to the ethinyl oestradiol in hormonal contraceptives, as oestrogens increase SHBG [34] .
Limitations of the current study include its crosssectional design, restricting conclusions on how oestradiol varies within women with type 1 diabetes over their reproductive years by duration of UnsuppOvFx. As oestradiol levels vary depending on timing within the menstrual cycle and by the presence of ovulation, the timing of the blood draw in the menstrual cycle was consistently scheduled. However, because documenting ovulation was not an objective of the ancillary study, confirmatory progesterone, FSH and LH levels were not measured. This was addressed statistically, and it was found that accounting for this variation by adjusting for the number of days before the first day of next menses that blood was drawn, and conducting sensitivity analyses on the subgroups of women with normal menstrual cycle lengths or without amenorrhoea, did not change the findings. Studies that include a direct assessment of ovulation will be useful in future work. While the age range may be seen as a limitation because oestradiol levels change with age, it can also be seen as a strength in that it allowed us to examine independent associations with age, while minimizing any potential confounding by matching on age, finding that age cannot replace UnsuppOvFx in the models. The strengths of this study include the following: a homogenous sample of women with type 1 diabetes with regard to race/ethnicity, menopausal status and disease duration; use of matched controls consisting of family and friends; measurement and examination of potential confounders; and testing for effect modification to better estimate the effect of type 1 diabetes on sex hormones.
In summary, oestradiol in women with type 1 diabetes appears to vary depending on the duration of their UnsuppOvFx, which will need to be confirmed in other cohorts. At shorter durations, women with type 1 diabetes may have lower levels, while at extended durations of UnsuppOvFx, they may have higher levels of oestradiol compared with controls. This unique hormonal milieu may be due to a complex and potentially synergistic mechanism of long-term exposure to supraphysiologic circulating insulin levels (despite hepatic hypoinsulinaemia) acting on ovarian follicular development and steroidogenesis. The potential long-term health consequences of what may be lower oestrogen at notably younger ages and excess oestrogen later in life for women with type 1 diabetes need to be investigated.
